TG Therapeutics (NASDAQ:TGTX) Reaches New 52-Week High - Time to Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $43.32 and last traded at $42.61, with a volume of 2055275 shares trading hands. The stock had previously closed at $42.99.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Trading Down 0.8 %

The company has a market capitalization of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business's 50-day simple moving average is $34.17 and its 200-day simple moving average is $30.18.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Remove Ads

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

A number of institutional investors have recently modified their holdings of the company. NorthCrest Asset Manangement LLC bought a new stake in TG Therapeutics in the 4th quarter valued at approximately $448,000. Vermillion Wealth Management Inc. bought a new stake in shares of TG Therapeutics in the fourth quarter worth $30,000. Castleark Management LLC boosted its holdings in TG Therapeutics by 25.2% during the fourth quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company's stock worth $6,362,000 after purchasing an additional 42,560 shares during the last quarter. Soleus Capital Management L.P. grew its position in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after purchasing an additional 146,702 shares in the last quarter. Finally, Wexford Capital LP acquired a new stake in TG Therapeutics in the 4th quarter valued at $421,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.